Phase 1/2 Trial of the XIAP Antisense Oligonucleotide (AEG35156) in Combination with Idarubicin and Cytarabiae in Patients with Relapsed/Refractory AML

被引：0
|
作者：
Schimmer, Aaron D. [1 ]
Estey, Elihu H. [7 ]
Borthakur, Gautam [7 ]
Carter, Bing [7 ]
Schiller, Gary J. [2 ]
Tallman, Martin S. [3 ]
Altman, Jessica K. [3 ]
Karp, Judith E. [4 ]
Kassis, Jeannine [5 ]
Jacob, Christine [6 ]
Morris, Stephen [6 ]
Jolivet, Jacques [6 ]
Andreeff, Michael [7 ]
机构：
[1] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[2] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA
[3] Northwestern Univ, Chicago, IL 60611 USA
[4] Johns Hopkins Univ, Baltimore, MD USA
[5] Hop Maison Neuve Rosemont, Montreal, PQ H1T 2M4, Canada
[6] Aegera Therapeut Inc, Montreal, PQ, Canada
[7] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
BLOOD | 2008年 / 112卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：283 / 284
页数：2
相关论文
共 50 条
  • [31] Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial
    Wang, Michael
    Fayad, Luis
    Wagner-Bartak, Nicolaus
    Zhang, Liang
    Hagemeister, Fredrick
    Neelapu, Sattva S.
    Samaniego, Felipe
    McLaughlin, Peter
    Fanale, Michelle
    Younes, Anas
    Cabanillas, Fernando
    Fowler, Nathan
    Newberry, Kate J.
    Sun, Luhong
    Young, Ken H.
    Champlin, Richard
    Kwak, Larry
    Feng, Lei
    Badillo, Maria
    Bejarano, Maria
    Hartig, Kimberly
    Chen, Wendy
    Chen, Yiming
    Byrne, Catriona
    Bell, Neda
    Zeldis, Jerome
    Romaguera, Jorge
    LANCET ONCOLOGY, 2012, 13 (07): : 716 - 723
  • [32] Phase-II trial of idarubicin, fludarabine, cytosine arabinoside, and filgrastim (Ida-FLAG) for treatment of refractory, relapsed, and secondary AML
    Steinmetz, HT
    Schulz, A
    Staib, P
    Scheid, C
    Glasmacher, A
    Neufang, A
    Franklin, J
    Tesch, H
    Diehl, V
    Wickramanayake, PD
    ANNALS OF HEMATOLOGY, 1999, 78 (09) : 418 - 425
  • [33] Phase-II trial of idarubicin, fludarabine, cytosine arabinoside, and filgrastim (Ida-FLAG) for treatment of refractory, relapsed, and secondary AML
    H. T. Steinmetz
    A. Schulz
    P. Staib
    C. Scheid
    A. Glasmacher
    A. Neufang
    J. Franklin
    H. Tesch
    V. Diehl
    P. Dias Wickramanayake
    Annals of Hematology, 1999, 78 : 418 - 425
  • [34] Phase II study of EL625, a p53 antisense oligonucleotide, and chemotherapy in refractory and relapsed acute myelogenous leukemia (AML).
    Freireich, EJ
    Kantarjian, H
    Garcia-Manero, G
    Ferrajoli, A
    Koller, C
    Estrov, Z
    Kornblau, S
    Laddie, N
    Smith, L
    Cortes, J
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 589S - 589S
  • [35] A Phase I dose finding study with CP-4055 (ELACYT\#8482;) plus idarubicin in patients with relapsed / refractory AML
    O'Brien, Susan
    Kantarjian, Hagop
    Ravandi, Farhad
    Rizzieri, David
    Padmanabhan, Swaminathan
    Jacobsen, Tove
    Staudacher, Karin
    Nilsson, Bo
    Giles, Francis
    CANCER RESEARCH, 2009, 69
  • [36] Phase II dosing study of cytarabine chemotherapy in combination with cenersen (EL625) and idarubicin in refractory and relapsed acute myelogenous leukemia (AML)
    Alvarado, Y.
    Kantarjian, H.
    Freireich, E. J.
    Garcia-Manero, G.
    Ferrajoli, A.
    Koller, C.
    Estrov, Z.
    Kornblau, S.
    Laddie, N.
    Smith, L.
    Cortes, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [37] Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma
    DuBois, Steven G.
    Mosse, Yael P.
    Fox, Elizabeth
    Kudgus, Rachel A.
    Reid, Joel M.
    McGovern, Renee
    Groshen, Susan
    Bagatell, Rochelle
    Maris, John M.
    Twist, Clare J.
    Goldsmith, Kelly
    Granger, M. Meaghan
    Weiss, Brian
    Park, Julie R.
    Macy, Margaret E.
    Cohn, Susan L.
    Yanik, Greg
    Wagner, Lars M.
    Hawkins, Randall
    Courtier, Jesse
    Lai, Hollie
    Goodarzian, Fariba
    Shimada, Hiroyuki
    Boucher, Najee
    Czarnecki, Scarlett
    Luo, Chunqiao
    Tsao-Wei, Denice
    Matthay, Katherine K.
    Marachelian, Araz
    CLINICAL CANCER RESEARCH, 2018, 24 (24) : 6142 - 6149
  • [38] A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma
    Richardson, Paul G.
    Xie, Wanling
    Jagannath, Sundar
    Jakubowiak, Andrzej
    Lonial, Sagar
    Raje, Noopur S.
    Alsina, Melissa
    Ghobrial, Irene M.
    Schlossman, Robert L.
    Munshi, Nikhil C.
    Mazumder, Amitabha
    Vesole, David H.
    Kaufman, Jonathan L.
    Colson, Kathleen
    McKenney, Mary
    Lunde, Laura E.
    Feather, John
    Maglio, Michelle E.
    Warren, Diane
    Francis, Dixil
    Hideshima, Teru
    Knight, Robert
    Esseltine, Dixie-Lee
    Mitsiades, Constantine S.
    Weller, Edie
    Anderson, Kenneth C.
    BLOOD, 2014, 123 (10) : 1461 - 1469
  • [39] Isatuximab in combination with cemiplimab in patients with relapsed/refractory multiple myeloma: A phase 1/2 study
    Lesokhin, Alexander
    LeBlanc, Richard
    Dimopoulos, Meletios A.
    Capra, Marcelo
    Carlo-Stella, Carmelo
    Karlin, Lionel
    Castilloux, Jean-Francois
    Forsberg, Peter
    Parmar, Gurdeep
    Tosikyan, Axel
    Pour, Ludek
    Ribrag, Vincent
    Ribolla, Rossella
    Abdallah, Al-Ola
    Le Roux, Nadia
    Dong, Liyan
    van de Velde, Helgi
    Mayrargue, Laurent
    Lepine, Lucie
    Mace, Sandrine
    Moreau, Philippe
    CANCER MEDICINE, 2023, 12 (09): : 10254 - 10266
  • [40] Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study
    Richardson, Paul G.
    Chanan-Khan, Asher A.
    Lonial, Sagar
    Krishnan, Amrita Y.
    Carroll, Michael P.
    Alsina, Melissa
    Albitar, Maher
    Berman, David
    Messina, Marianne
    Anderson, Kenneth C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2011, 153 (06) : 729 - 740
12345